½ÃÀ庸°í¼­
»óǰÄÚµå
1601291

STD °Ë»ç ½ÃÀå : À¯Çüº°, Á¦Ç° À¯Çüº°, °Ë»ç ¼³Á¤º°, ÀûÀÀÁõº°, ÃÖÁ¾ »ç¿ëÀÚº° - ¼¼°è ¿¹Ãø(2025-2030³â)

STD Testing Market by Type (Blood Tests, Lumbar Puncture, Swab Tests), Product Type (Instruments, Reagents & Kits), Test Settings, Indication, End-user - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 194 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

STD °Ë»ç ½ÃÀåÀº 2023³â¿¡ 94¾ï 4,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024³â¿¡´Â 99¾ï 7,000¸¸ ´Þ·¯¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 5.90%·Î ¼ºÀåÇϸç 2030³â¿¡´Â 141¾ï 1,000¸¸ ´Þ·¯ ±×·¸´Ù°í ¿¹ÃøµË´Ï´Ù.

STD °Ë»ç ½ÃÀå¿¡´Â Ŭ¶ó¹Ìµð¾Æ, ÀÓÁú, HIV, ¸Åµ¶À» Æ÷ÇÔÇÏÁö¸¸ ÀÌ¿¡ ±¹ÇѵÇÁö ¾Ê´Â ¼ºº´À» °ËÃâÇϵµ·Ï ¼³°èµÈ ±¤¹üÀ§ÇÑ Áø´Ü °Ë»ç°¡ Æ÷ÇԵ˴ϴÙ. »ó½Â, °øÁß º¸°Ç ÀÇ½Ä Áõ°¡ Á¶±â Áø´Ü°ú Ä¡·á °³ÀÔ¿¡ ´ëÇÑ ³ë·ÂÀ¸·Î ÀÎÇØ º´¿ø, Ŭ¸®´Ð, ÀçÅà °ü¸® ¹× ÃÖÁ¾ »ç¿ëÀÚ´Â °Ç°­ °ü¸® Á¦°ø¾÷ü, °³ÀÎ ¼ÒºñÀÚ ¹× °øÁß º¸°Ç ±â°üÀÔ´Ï´Ù. ±×¸®°í Á¤È®ÇÑ °Ë»ç¸¦ °¡´ÉÇÏ°Ô ÇÏ´Â ±â¼úÀÇ Áøº¸, STD °Ë»ç Ä·ÆäÀο¡ ´ëÇÑ Á¤ºÎ Áö¿ø Áõ°¡, ÀçÅà ÇコÄÉ¾î ¼Ö·ç¼ÇÀ̳ª µðÁöÅÐ ÇコÄÉ¾î ¼Ö·ç¼ÇÀÇ ¼ö¿ë È®´ë µîÀÇ ¿äÀÎÀ¸·ÎºÎÅÍ Å« ¿µÇâÀ» ¹Þ°í ÀÖ½À´Ï´Ù. °ÝÀÇ·á¿ÍÀÇ ÅëÇÕ, ¸ð¹ÙÀÏ ¾Û ±â¹Ý °Ë»ç ¼Ö·ç¼Ç, º¸´Ù °í°¨µµ·Î ƯÀÌÀûÀÎ ºÐ¼®ÀÇ °³¹ß µî ºÐ¾ß¿¡¼­ ½ÃÀå ÁøÃâ±â¾÷ÀÌ Çõ½ÅÀ» ÀÏÀ¸Å³ ±âȸ¸¦ ¸¸µé¾î³»°í ÀÖ½À´Ï´Ù. ±×·¯³ª ½ÃÀå ¼ºÀå¿¡´Â ¼ºº´À» Ãë ·Ñ¸µ Æí°ß, ¹Ì¹ß´Þ Áö¿ªÀÇ ÀÎ½Ä ºÎÁ·, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ ¹× »óȯ Á¤Ã¥¿¡ °üÇÑ ¹®Á¦ µîÀÇ Á¦¾àÀÌ ÀÖ½À´Ï´Ù. ºñ¿ë ´ëÈ¿°úÀÇ °Ë»ç ¼Ö·ç¼ÇÀÇ ¿¬±¸¿¡ ÁÖ·ÂÇÒ ¼ö ÀÖ½À´Ï´Ù.À̳뺣À̼ÇÀÇ ÁÖ¿ä ºÐ¾ß¿¡´Â ÀÚ¿øÀÌ ÇÑÁ¤µÈ ȯ°æ¿¡¼­ÀÇ °Ë»ç¸¦ À§ÇÑ Áø´Ü Ç÷§ÆûÀÇ ¼ÒÇüÈ­³ª, STD °¨¿° ÆÐÅÏÀÇ ¿¹Ãø ºÐ¼®¿¡ÀÇ AIÀÇ ¹ÝÀÀ »Ó¸¸ ¾Æ´Ï¶ó ±â¼ú ±â¾÷°úÀÇ ÆÄÆ®³Ê½ÊÀ» ÃËÁøÇÏ¿© Á¤È®ÇÑ °Ë»ç ¼­ºñ½º Á¦°øÀ» ´õ¿í °­È­ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¸¶¸£ Ä¡Ç÷º½º °Ë»ç¿Í °³ÀÎÈ­ °Ç°­ °ü¸® Á¦°ø°ú °°Àº »õ·Î¿î µ¿Çâ¿¡ Å« °ü½ÉÀÌ ÇÊ¿äÇÕ´Ï´Ù. ¼³¸³¿¡ ÇʼöÀûÀÔ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ(2023) 94¾ï 4,000¸¸ ´Þ·¯
¿¹Ãø³â(2024) 99¾ï 7,000¸¸ ´Þ·¯
¿¹Ãø³â(2030) 141¾ï 1,000¸¸ ´Þ·¯
CAGR(%) 5.90%

½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈ­ÇÏ´Â STD °Ë»ç ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

STD °Ë»ç ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ë¿¡ ÀÇÇØ º¯¸ð¸¦ ÀÌ·ç°í ÀÖ½À´Ï´Ù. ºñÁî´Ï½º ±âȸ¸¦ ȹµæÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦ÀûÀÎ ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ °æ°¨ÇÒ ¼ö ÀÖÀ½°ú µ¿½Ã¿¡, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ëÀ̳ª ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ¼¼°èÀÇ ¼º °¨¿°ÁõÀÇ ÀÌȯÀ²°ú À¯º´·üÀÇ »ó½Â
    • ±³À° Ä·ÆäÀÎÀ» ÅëÇÑ ¼ºº´¿¡ ´ëÇÑ ÀÇ½Ä Áõ°¡
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • STD °Ë»ç Á¦Ç°ÀÇ ½ÂÀο¡ °üÇÑ ¾ö°ÝÇÑ ±ÔÁ¦ °¡À̵å¶óÀο¡ °üÇÑ ¹®Á¦
  • ½ÃÀå ±âȸ
    • ¼ºº´ Áø´Ü¿¡ À־ÀÇ ±â¼úÀû Áøº¸ÀÇ °è¼Ó
    • STD °Ë»çÀÇ Ã¤¿ëÀ» ÃËÁøÇϱâ À§ÇÑ Àü±¹ÀûÀÎ ½ºÅ©¸®´× °Ë»çÀÇ ½Ç½Ã Áõ°¡
  • ½ÃÀåÀÇ °úÁ¦
    • STD °Ë»ç Àü¹® Ŭ¸®´ÐÀÇ ÁøÂû¿¡ ¼ö¹ÝÇÏ´Â »çȸÀû ½ºÆ¼±×¸¶

Porter's Five Forces: STD °Ë»ç ½ÃÀåÀ» Ž»öÇÏ´Â Àü·« µµ±¸

Porter's Five Forces ÇÁ·¹ÀÓ ¿öÅ©´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ±â¹ýÀ» Á¦°øÇÕ´Ï´Ù. ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ¼öÀÖ´Â ´õ °­ÀÎÇÑ ½ÃÀå¿¡¼­ Æ÷Áö¼Å´×À» º¸Àå ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : STD °Ë»ç ½ÃÀå¿¡¼­ ¿ÜºÎ ¿µÇâÀ» ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº STD °Ë»ç ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ»ÇÕ´Ï´Ù. ¸¦ Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù. PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀûÀÎ À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ¿¹ÃøÇÒ ¼ö ÀÖ´Â Àû±ØÀûÀÎ ÀÇ»ç °áÁ¤À» ÇÒ Áغñ°¡ µÇ¾ú½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® STD °Ë»ç ½ÃÀå °æÀï ±¸µµ ÆÄ¾Ç

STD °Ë»ç ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ºÐ¸í ÀÌ ºÐ¼®À» ÅëÇØ ½ÃÀå ÁýÁß, ´ÜÆíÈ­, ÅëÇÕ µ¿ÇâÀ» ¹àÇô³»°í º¥´õ´Â °æÀïÀÌ Ä¡¿­ÇØÁö¸é¼­ ÀÚ»çÀÇ ÁöÀ§¸¦ ³ôÀÌ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» Çϱâ À§ÇØ ÇÊ¿äÇÑ Áö°ß ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º STD °Ë»ç ½ÃÀå¿¡¼­ °ø±Þ¾÷üÀÇ ¼º´É Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â STD °Ë»ç ½ÃÀå¿¡¼­ º¥´õ¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ±âº» °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù. ³× °¡Áö »çºÐ¸éÀº °ø±Þ¾÷ü¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ±¸ºÐÇÏ¿© »ç¿ëÀÚ°¡ Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê ¹× ¼Ö·ç¼ÇÀ» ½Äº°ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â Á¾ÇÕÀûÀÎ ½ÃÀå ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõ: ¾÷°è ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅ͸¦ Æ÷ÇÔÇÑ ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀåÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÏ°í ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡ÇÏ¸ç ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù¾çÈ­: ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä Áøº¸, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú Áøº¸ µîÀ» °ËÁõÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÃÖ÷´Ü ±â¼ú, R&D Ȱµ¿, Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¶ÇÇÑ ÀÌÇØ°ü°èÀÚ°¡ ÃæºÐÇÑ Á¤º¸¸¦ ¾ò°í ÀÇ»ç°áÁ¤À» ÇÒ ¼ö ÀÖµµ·Ï Áß¿äÇÑ Áú¹®¿¡ ´ë´äÇϰí ÀÖ½À´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå ¿¹ÃøÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹® ¹× Áö¿ªÀº ¾îµðÀԴϱî?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5. º¥´õ ½ÃÀå ÁøÀÔ¡¤Ã¶¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
    • °úÁ¦
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ¹ý·ü
    • ȯ°æ

Á¦6Àå STD °Ë»ç ½ÃÀå : À¯Çüº°

  • Ç÷¾×°Ë»ç
  • ¿äÃß ÃµÀÚ
  • ½º¿Ò °Ë»ç
  • ¼Òº¯ °Ë»ç

Á¦7Àå STD °Ë»ç ½ÃÀå : Á¦Ç° À¯Çüº°

  • ±â±â
  • ½Ã¾à ¹× ŰƮ

Á¦8Àå STD °Ë»ç ½ÃÀå : Å×½ºÆ® ¼³Á¤º°

  • ¿¬±¸½Ç
  • Æ÷ÀÎÆ® ¿Àºê Äɾî

Á¦9Àå STD °Ë»ç ½ÃÀå : ÀûÀÀÁõº°

  • Ŭ¶ó¹Ìµð¾Æ
  • »ý½Ä±â Ç츣Æä½º
  • ÀÓÁú
  • BÇü °£¿°
  • HIV/¿¡ÀÌÁî
  • ÀÎÀ¯µÎÁ¾ ¹ÙÀÌ·¯½º
  • ¸Åµ¶

Á¦10Àå STD °Ë»ç ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°

  • Áø´Ü¼¾ÅÍ
  • º´¿ø ¹× Ŭ¸®´Ð

Á¦11Àå ¾Æ¸Þ¸®Ä«ÀÇ STD °Ë»ç ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦12Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ STD °Ë»ç ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦13Àå À¯·´¡¤Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ STD °Ë»ç ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦14Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼®, 2023
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®

±â¾÷ ¸ñ·Ï

  • Abbott Laboratories
  • Accuquik by AdvaCare Pharma
  • Alpine Biomedicals Pvt. Ltd.
  • ARCpoint Labs
  • Becton, Dickinson and Company
  • Bio Lab Diagnostics(I) Private Limited
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • BioReference Health, LLC by OPKO HEALTH, INC.
  • Danaher Corporation
  • Daye Limited
  • Everlywell, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Getein Biotech, Inc.
  • Grifols, SA
  • Hologic, Inc.
  • JAL Medical by OK Biotech Co. Ltd.
  • Laboratory Corporation of America Holdings
  • LifeCell
  • Lorne Laboratories Limited by Calibre Scientific
  • Meridian Bioscience Inc. by SD Biosensor, Inc.
  • OraSure Technologies, Inc.
  • Personalabs
  • Qiagen NV
  • Quest Diagnostics, Inc.
  • Randox Laboratories Ltd.
  • Seegene Inc.
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • Viatris Inc.
  • Wondfo Biotech Co., Ltd.
BJH 24.12.06

The STD Testing Market was valued at USD 9.44 billion in 2023, expected to reach USD 9.97 billion in 2024, and is projected to grow at a CAGR of 5.90%, to USD 14.11 billion by 2030.

The STD testing market encompasses a wide array of diagnostic tests designed to detect sexually transmitted diseases, including, but not limited to, chlamydia, gonorrhea, HIV, and syphilis. The necessity for STD testing stems from rising infection rates, greater public health awareness, and initiatives for early diagnosis and treatment intervention. Its application spans hospitals, clinics, and homecare settings, with end-users comprising healthcare providers, individual consumers, and public health organizations. The market is significantly influenced by factors such as technological advancements enabling rapid and accurate testing, increased government support for STD testing campaigns, and growing acceptance of at-home and digital healthcare solutions. These factors create opportunities for market players to innovate in areas such as telehealth integration, mobile app-based testing solutions, and the development of more sensitive and specific assays. However, market growth is challenged by limitations such as stigma surrounding STDs, lack of awareness in underdeveloped regions, and issues related to regulatory approvals and reimbursement policies. To address these, businesses could invest in educational marketing campaigns, collaborate with public health entities, and focus on research for cost-effective testing solutions. Key areas of innovation include the miniaturization of diagnostic platforms for testing in resource-limited settings and the application of AI for predictive analyses in STD transmission patterns. Additionally, fostering partnerships with technology firms can further enhance the delivery of precise testing services. The market's dynamic nature necessitates agility and foresight, with significant attention needed on emerging trends like multiplex testing and personalized healthcare delivery. Keeping pace with regulatory changes and potential policy shifts in healthcare funding will be essential for sustained business growth and establishing a competitive edge.

KEY MARKET STATISTICS
Base Year [2023] USD 9.44 billion
Estimated Year [2024] USD 9.97 billion
Forecast Year [2030] USD 14.11 billion
CAGR (%) 5.90%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving STD Testing Market

The STD Testing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising incidence and prevalence of sexually transmitted diseases worldwide
    • Increasing awareness about STDs through education campaigns
  • Market Restraints
    • Issues regarding strict regulatory guidelines for approval of STD testing products
  • Market Opportunities
    • Ongoing technical advancements in STD disease diagnostics
    • Increasing implementation of nationwide screening tests to encourage the adoption of STD testing
  • Market Challenges
    • Social stigma associated with visiting specialized STD testing clinics

Porter's Five Forces: A Strategic Tool for Navigating the STD Testing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the STD Testing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the STD Testing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the STD Testing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the STD Testing Market

A detailed market share analysis in the STD Testing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the STD Testing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the STD Testing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the STD Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Accuquik by AdvaCare Pharma, Alpine Biomedicals Pvt. Ltd., ARCpoint Labs, Becton, Dickinson and Company, Bio Lab Diagnostics (I) Private Limited, Bio-Rad Laboratories, Inc., bioMerieux SA, BioReference Health, LLC by OPKO HEALTH, INC., Danaher Corporation, Daye Limited, Everlywell, Inc., F. Hoffmann-La Roche Ltd., Getein Biotech, Inc., Grifols, S.A., Hologic, Inc., JAL Medical by OK Biotech Co. Ltd., Laboratory Corporation of America Holdings, LifeCell, Lorne Laboratories Limited by Calibre Scientific, Meridian Bioscience Inc. by SD Biosensor, Inc., OraSure Technologies, Inc., Personalabs, Qiagen N.V., Quest Diagnostics, Inc., Randox Laboratories Ltd., Seegene Inc., Siemens Healthineers AG, Thermo Fisher Scientific Inc., Viatris Inc., and Wondfo Biotech Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the STD Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Blood Tests, Lumbar Puncture, Swab Tests, and Urine Tests.
  • Based on Product Type, market is studied across Instruments and Reagents & Kits.
  • Based on Test Settings, market is studied across Laboratory and Point of Care.
  • Based on Indication, market is studied across Chlamydia, Genital Herpes, Gonorrhea, Hepatitis B, HIV/AIDS, Human Papillomavirus, and Syphilis.
  • Based on End-user, market is studied across Diagnostic Centers and Hospitals & Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidence and prevalence of sexually transmitted diseases worldwide
      • 5.1.1.2. Increasing awareness about STDs through education campaigns
    • 5.1.2. Restraints
      • 5.1.2.1. Issues regarding strict regulatory guidelines for approval of STD testing products
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing technical advancements in STD disease diagnostics
      • 5.1.3.2. Increasing implementation of nationwide screening tests to encourage the adoption of STD testing
    • 5.1.4. Challenges
      • 5.1.4.1. Social stigma associated with visiting specialized STD testing clinics
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Increasing preference for swab tests for STD testing for their non-invasive nature
    • 5.2.2. Product Type: Need for high-throughput instruments for high-volume testing environments
    • 5.2.3. Test Settings: Preference for POC tests for their unmatched convenience and speed
    • 5.2.4. Indication: Rising occurrence of chlamydia and need for sophisticated testing technologies
    • 5.2.5. End-user: Expanding usage of STD testing at diagnostic centers for quick turnaround time
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. STD Testing Market, by Type

  • 6.1. Introduction
  • 6.2. Blood Tests
  • 6.3. Lumbar Puncture
  • 6.4. Swab Tests
  • 6.5. Urine Tests

7. STD Testing Market, by Product Type

  • 7.1. Introduction
  • 7.2. Instruments
  • 7.3. Reagents & Kits

8. STD Testing Market, by Test Settings

  • 8.1. Introduction
  • 8.2. Laboratory
  • 8.3. Point of Care

9. STD Testing Market, by Indication

  • 9.1. Introduction
  • 9.2. Chlamydia
  • 9.3. Genital Herpes
  • 9.4. Gonorrhea
  • 9.5. Hepatitis B
  • 9.6. HIV/AIDS
  • 9.7. Human Papillomavirus
  • 9.8. Syphilis

10. STD Testing Market, by End-user

  • 10.1. Introduction
  • 10.2. Diagnostic Centers
  • 10.3. Hospitals & Clinics

11. Americas STD Testing Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific STD Testing Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa STD Testing Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Strategic Alliance Advances Self-Test Solutions for Sexually Transmitted Diseases
    • 14.3.2. imaware Expands its Portfolio through binx health's Consumer Division Purchase
    • 14.3.3. FDA Approves Advanced At-home Chlamydia and Gonorrhea Test
    • 14.3.4. British Startup Launches Tampon That Offers STI Screening
    • 14.3.5. iHealth Launches Home Collection Kit for STD Testing
    • 14.3.6. Aptitude Medical Systems' Innovative Approach to Combat Sexually Transmitted Infections (STIs)
    • 14.3.7. LifeCell International Revolutionizes STD and HPV Screening with At-Home Test Kits
    • 14.3.8. Breakthrough 20-Minute Test for Gonorrhea and Chlamydia by Linear Diagnostics
    • 14.3.9. US BioTek's Innovative At-Home Testing Solutions
    • 14.3.10. Visby Medical Achieves FDA Clearance for Advanced Sexual Health Diagnostic Tool
    • 14.3.11. Mylab Launches a Range of Rapid Tests for STDs
    • 14.3.12. Strategic Partnership between Maternova and MedMira Enhances Global Access to Rapid Diagnostic Tests for Infectious Diseases
    • 14.3.13. Innovative Partnership Tackles STI Spike Among Gen Z with At-Home Testing Solutions
    • 14.3.14. Meridian Bioscience Joins Forces with SD Biosensor and SJL Partners

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Accuquik by AdvaCare Pharma
  • 3. Alpine Biomedicals Pvt. Ltd.
  • 4. ARCpoint Labs
  • 5. Becton, Dickinson and Company
  • 6. Bio Lab Diagnostics (I) Private Limited
  • 7. Bio-Rad Laboratories, Inc.
  • 8. bioMerieux SA
  • 9. BioReference Health, LLC by OPKO HEALTH, INC.
  • 10. Danaher Corporation
  • 11. Daye Limited
  • 12. Everlywell, Inc.
  • 13. F. Hoffmann-La Roche Ltd.
  • 14. Getein Biotech, Inc.
  • 15. Grifols, S.A.
  • 16. Hologic, Inc.
  • 17. JAL Medical by OK Biotech Co. Ltd.
  • 18. Laboratory Corporation of America Holdings
  • 19. LifeCell
  • 20. Lorne Laboratories Limited by Calibre Scientific
  • 21. Meridian Bioscience Inc. by SD Biosensor, Inc.
  • 22. OraSure Technologies, Inc.
  • 23. Personalabs
  • 24. Qiagen N.V.
  • 25. Quest Diagnostics, Inc.
  • 26. Randox Laboratories Ltd.
  • 27. Seegene Inc.
  • 28. Siemens Healthineers AG
  • 29. Thermo Fisher Scientific Inc.
  • 30. Viatris Inc.
  • 31. Wondfo Biotech Co., Ltd.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦